Evaluation of the aspects of reproductive toxicity of the new anti-tuberculosis drug thiosonide
- Authors: Savchenko A.Y.1, Burenkov M.S2, Baidin P.S2, Ramenskaya G.V3, Perova N.V4, Kukes V.G5, Shilova N.V6
-
Affiliations:
- Scientific Center for Biomedical Technologies FMBA of Russia
- Pharm-Sintez
- Sechenov University
- Аutonomous Non-Commercial Organization Institute of Medical and Biological Research and technologies
- Branch “Clinical Pharmacology", Scientific Center for Biomedical Technologies FMBA of Russia
- Reprohelp Ltd
- Issue: Vol 28, No 6 (2021)
- Pages: 95-99
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313171
- DOI: https://doi.org/10.18565/pharmateca.2021.6.95-99
- ID: 313171
Cite item
Open Access
Access granted
Abstract
Background. Globally, the number of cases of tuberculosis with pathogen resistance, sometimes to all available anti-tuberculosis drugs (anti-TB drugs), is increasing. This fact prompts the development of new anti-TB drugs that are effective against multidrug-resistant tuberculosis. Objective. Evaluation of the toxic effect on the fetus and embryo of a new anti-tuberculosis drug of the diarylquinoline group with the working name thiosonide in an experiment on rats. Methods. To study the effect of thiosonide on embryonic development, experiments were carried out in 30 pregnant white outbred rats with an initial weight of 220-250 g. Antenatal effect of thiosonide on postnatal development was studied in experiments on 20 outbred white rats, 10 animals per group. Impact assessment criteria: weight dynamics and physical development of infant rats, development of physical activity (horizontal rope test); formation of sensory-motor reflexes (righting reflex and cliff avoidance reflex), behavior in an open field (registration of horizontal and vertical motor activity, exploratory and emotional reactions, grooming). Results. The absence of embryotoxic and fetotoxic effects of thiosonide administered to pregnant rats orally at doses of 10 and 100 mg/ kg was shown. The rates of embryonic death, body weight and fetal size were close to the control group values. In experiments studying the effect of thiosonide intake by pregnant rats on the postnatal development of rats no developmental deviations were revealed. The physical development of infant rats in the experimental group did not differ from that in the control group. It was found that the righting reflex, cliff avoidance reflex and behavior in the open field on the 5th day of life were formed in all infant rats in both experimental and control groups and corresponded to the physiological ranges. Conclusion. Thiosonide has no embryotoxic and fetotoxic effects, which makes it possible to consider it as a promising drug for the treatment of tuberculosis.
Full Text
About the authors
A. Yu Savchenko
Scientific Center for Biomedical Technologies FMBA of Russia
M. S Burenkov
Pharm-Sintez
P. S Baidin
Pharm-Sintez
G. V Ramenskaya
Sechenov University
N. V Perova
Аutonomous Non-Commercial Organization Institute of Medical and Biological Research and technologies
V. G Kukes
Branch “Clinical Pharmacology", Scientific Center for Biomedical Technologies FMBA of Russia
N. V Shilova
Reprohelp Ltd
Email: nvshilova@gmail.com
Cand. Sci. (Med.), Director
References
- Uplekar M., Weil D., Lonnroth K., et al. WHO's new end TB strategy. Lancet. 2015;385:1799-1801.
- Филинюк О.В., Фелькер И.Г., Янова Г. В. и др. Факторы риска неэффективной химиотерапии больных туберкулезом с множественной лекарственной устойчивостью. Туберкулез и болезни легких. 2014;(1):20-6.
- Щегерцов Д.Ю., Филинюк О.В., Буйнова Л.Н. и др. Нежелательные побочные реакции при лечении больных туберкулезом с множественной лекарственной устойчивостью возбудителя. Туберкулез и болезни легких. 2018;96(3):35 43
- Qiu J., Wang C., Pan X., APACHE-II score for anti-tuberculosis tolerance in critically ill patients: a retrospective study. BMC Infect Dis. 2019;19(1):106. doi: 10.1186/s12879-019 3751-7
- Меньшикова Л.А. Фармакокинетическое исследование оригинального лекарственного средства тиозонида. Дисс. канд. фарм. наук. М., 2016
- Бочарова И.В., Буренков М.С., Лепеха Л.Н., и др. Доклинические исследования специфической активности нового противотуберкулезного препарата тиозонид. Туберкулез и болезни легких. 2014;(6):46-50
- Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К, 2012. 944 с
- Боровиков В.П., Боровиков И.П. Статистический анализ и обработка данных в среде Windows. М.: Филинъ, 1997. 608 с
- Schaefer C. Arzneimitteltherapiesicherheit in der Schwangerschaft - eine besondere Herausforderung [Drug safety in pregnancy-a particular challenge]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018;61(9):1129-38. German. Doi: 10.1007/ s00103-018-2798-8.
- Escobar-Huerfano F, Gomez-Olivan L.M., Luja-Mondragon M., et al. Embryotoxic and teratogenic profile of tretracycline at environmentally relevant concentrations on Cyprinus carpio. Chemosphere. 2020;240:124969. Doi: 10.1016/j. chemosphere.2019.124969.
- Velichka D., Ivana A., Haruaki T., et al. Experimental and clinical studies on Rifacinna - the new effective antituberculous drug (review). Recent Pat Antiinfect Drug Discov. 2010;5(1):76-90. doi: 10.2174/157489110790112572.
- Jaspard M., Elefant-Amoura E., Melonio I., et al. Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman. Emerg Infect Dis. 2017;23(10):1731-32. doi: 10.3201/eid2310.161398.
Supplementary files
